Breaking News
December 14, 2018 - Blood test helps identify distinct molecular signatures in children with cystic fibrosis
December 14, 2018 - Scientists use water to track electrical activity of nerve cells
December 14, 2018 - Recurrence of urinary tract infection may depend on bacterial strain, study shows
December 14, 2018 - GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
December 14, 2018 - Partial Thromboplastin Time (PTT) Test: MedlinePlus Lab Test Information
December 14, 2018 - Common tactics for health promotion at work may be detrimental to employees with obesity
December 14, 2018 - Myths about migration and health not supported by available evidence
December 14, 2018 - Recent findings on rare genetic disorder may help develop new treatment options
December 14, 2018 - New drug shows promise in treating sarcomas
December 14, 2018 - Scientists perform lung lavage as new approach for tuberculosis diagnosis in rhinoceros
December 14, 2018 - Recent winners of the Nobel Medicine Prize
December 14, 2018 - KHN’s ‘What the Health?’ Insurance enrollment is lagging — and there are lots of reasons why
December 14, 2018 - Study assesses safety and efficacy of new treatment for pancreatic cancer
December 14, 2018 - Study finds drug targets for Ebola, Dengue, and Zika viruses
December 14, 2018 - Study highlights need for personalized approach to treat ICU acquired delirium
December 14, 2018 - Massage helps relieve pain, improve mobility in patients with knee osteoarthritis
December 14, 2018 - Researchers explore home healthcare nurses’ knowledge attitudes toward infection control
December 14, 2018 - Average outpatient visit in the U.S. costs nearly $500, shows new study
December 14, 2018 - Reference Infliximab, Biosimilar Equivalent for Crohn’s Disease
December 14, 2018 - New contact lens to treat eye injuries
December 14, 2018 - Acne could have a genetic basis find researchers promising new cure
December 14, 2018 - Higher physical activity associated with improved mood
December 14, 2018 - New UGA study points to optimal hypertension treatment for stroke patients
December 14, 2018 - Study highlights factors that can reduce food cravings
December 14, 2018 - Researchers discover Ebola-fighting protein in human cells
December 14, 2018 - Fentanyl surpasses heroin in cause of U.S. drug overdose deaths
December 14, 2018 - When Heart Attack Strikes, Women Often Hesitate to Call for Help
December 14, 2018 - A warning about costume contacts
December 14, 2018 - Study examines link between peripheral artery disease and heart attack
December 14, 2018 - Researchers develop biotechnological tool to produce antifungal proteins in plants
December 14, 2018 - 3D-printed adaptive aids can benefit patients with arthritis
December 14, 2018 - Chronic bullying during adolescence impacts mental health
December 14, 2018 - Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics
December 13, 2018 - Importance of cell cycle and cellular senescence in the placenta discovered
December 13, 2018 - Gold “nanoprisms” open new window into vessels and single cells
December 13, 2018 - Research findings could lead to new targets for cancer-fighting therapeutics
December 13, 2018 - Butantan Institute signs collaboration agreement with MSD to develop dengue vaccines
December 13, 2018 - Study explores how patients want to discuss symptoms with doctors
December 13, 2018 - RUDN medics first to gather scattered data on hepatitis morbidity in Somalia
December 13, 2018 - Age and gender disparities found in use of bed nets to prevent malaria in sub-Saharan Africa
December 13, 2018 - Caffeine therapy benefits developing brains of premature babies
December 13, 2018 - New review focuses on electrospinning techniques used in musculoskeletal tissue engineering
December 13, 2018 - A new division focused on human immune system
December 13, 2018 - Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of Fintepla (ZX008) in Dravet Syndrome
December 13, 2018 - BCR ABL Genetic Test: MedlinePlus Lab Test Information
December 13, 2018 - Caffeinated beverages during pregnancy linked to lower birth weight babies
December 13, 2018 - Stanford Medicine Health Trends Report examines opportunity to democratize health care
December 13, 2018 - Obsessive-compulsive disorder may protect individuals from obesity
December 13, 2018 - Scientists investigate how a painful event is processed in the brain
December 13, 2018 - Genetic study reveals new insights into underlying causes of moderate-to-severe asthma
December 13, 2018 - Study uncovers new genetic clues to frontotemporal dementia
December 13, 2018 - Vitamin C supplementation for pregnant smokers may reduce harm to infants’ lungs
December 13, 2018 - New study reveals yin-yang personality of dopamine
December 13, 2018 - Research identifies nerve-signaling pathway behind sustained pain after injury
December 13, 2018 - Children with high levels of callous traits show widespread differences in brain structure
December 13, 2018 - Long-term Benefit of Steroid Injections for Knee Osteoarthritis Challenged
December 13, 2018 - Adding new channels to the brain remote control
December 13, 2018 - In the Spotlight: A different side of neuroscience
December 13, 2018 - Medical Marvels: Using immunotherapy for melanoma that spread to the brain
December 13, 2018 - Puzzles do not keep dementia away finds study
December 13, 2018 - New mouse model shows potential for rapid identification of promising muscular dystrophy therapies
December 13, 2018 - Study reveals urban and rural differences in prenatal exposure to essential and toxic elements
December 13, 2018 - New collaborative partnership in quest of novel antibiotics
December 13, 2018 - Single tau molecule holds clues to help diagnose neurodegeneration in its earliest stages
December 13, 2018 - AHA Scientific Statement: Low Risk of Side Effects for Statins
December 13, 2018 - What Is Acute Flaccid Myelitis?
December 13, 2018 - How bereaved people control their thoughts without knowing it
December 13, 2018 - Health care democratization underway, according to 2nd annual Stanford Medicine Health Trends Report | News Center
December 13, 2018 - Going Beyond a Single Color
December 13, 2018 - London-based startup launches ‘’ aiming to clean up CBD industry
December 13, 2018 - Loss of tight junction barrier protein results in gastric cancer development
December 13, 2018 - Novel way to efficiently deliver anti-parasitic medicines
December 13, 2018 - RKI publishes new data on disease prevention and utilization of medical services
December 13, 2018 - High-tech, flexible patches sewn into clothes could help to stay warm
December 13, 2018 - The CCA releases three reports on requests for medical assistance in dying
December 13, 2018 - Restoring Hair Growth on Scarred Skin? Mouse Study Could Show the Way
December 13, 2018 - Probiotic use may reduce antibiotic prescriptions, researchers say
December 13, 2018 - Drug repositioning strategy identifies potential new treatments for epilepsy
December 13, 2018 - Chronic rhinitis associated with hospital readmissions for asthma and COPD patients
December 13, 2018 - Food poisoning discovery could save lives
Enzalutamide Safe In Seizure-Prone Prostate CA Patients

Enzalutamide Safe In Seizure-Prone Prostate CA Patients

image_pdfDownload PDFimage_print

Action Points

  • The androgen receptor inhibitor enzalutamide (Xtandi) did not raise seizure incidence when used at a dose of 160 mg/day in men with metastatic castration-resistant prostate cancer (mCRPC) at risk for seizures, in a multicenter, multinational trial.
  • Note that the data, along with the previously established efficacy profile, suggest that enzalutamide does not predispose to seizures and may be safely used in men with metastatic prostate cancer who have risk factors for seizure.

In men with metastatic castration-resistant prostate cancer (mCRPC) at risk for seizures, the androgen receptor inhibitor enzalutamide (Xtandi) didn’t raise seizure incidence when used at a dose of 160 mg/day, researchers found in a manufacturer-sponsored study.

Confirmed seizure incidence in the Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide (UPWARD) was 2.6 per 100 patient-years, according to Susan Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues.

That’s about the same as the incidence previously calculated in a large retrospective analysis in the U.S., at 2.8 per 100 patient-years in patients with mCRPC and seizure risk factors who never took the drug, Slovin and colleagues reported online in JAMA Oncology.

“These data suggest that enzalutamide did not increase seizure incidence in men with mCRPC and seizure risk factors and is an option for patients with seizure risk factors,” the researchers wrote. “However, it should be used with caution and input from neurology specialists.”

“The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety,” they added.

Jim Hu, MD, MPH, of New York Presbyterian/Weill Cornell Medicine in New York City, who wasn’t involved in the study, noted that the results contrast to those of a prior study, but they do suggest that “enzalutamide does not predispose to seizure. This demonstrates that enzalutamide may be safely used in men with metastatic prostate cancer who have risk factors for seizure.”

UPWARD was initiated following requests for additional safety information from the FDA and the European Medicines Agency. Although enzalutamide is known to prolong survival in men with mCRPC, phase I and II studies reported seizures in 3 of 140 (2%) enzalutamide-treated patients at doses greater than 360 mg/day.

Controlled clinical trials such as AFFIRM, PREVAIL, TERRAIN, and STRIVE have shown that with 160 mg of oral enzalutamide daily, only 0.5% of patients experienced seizure. However, patients with a history of seizure or risk factors were excluded from these trials, the researchers noted.

For UPWARD, they evaluated 423 patients at 73 sites in 20 countries, all of whom had at least one risk factor for seizure, including medications that lowered seizure threshold (57.2%); history of brain injury (26.5%); and history of cerebrovascular accident or transient ischemic attack (22.2%).

All patients received oral enzalutamide at a dose of 160 mg/day for an initial 4-month treatment period, and were given the option to extend treatment for one year.

Overall, 4 out of 366 evaluable patients (1.1%) had at least one confirmed seizure within 4 months of starting enzalutamide. The seizures were considered enzalutamide-related in 3 of the 4 patients. In addition, 3 patients (0.8%) had a seizure in the 4-month period after the study ended.

All 423 patients were included in the safety analysis. The majority (84.4%) experienced at least one treatment-emergent adverse event: 33.3% had at least one serious treatment-emergent adverse event, and 6.9% had at least one drug-related serious adverse event.

A total of 66 patients (15.6%) permanently discontinued treatment as a result of a drug-related AE, and three of these patients had a seizure, the researchers reported.

During the 4-month study period or within 30 days of the treatment ending, there were 38 deaths (9%), four of which were considered possibly drug-related. One patient died of cerebral hemorrhage, one of mCRPC progression, one experienced sudden cardiac death, and another had general deterioration. No seizure-related deaths were reported.

Study limitations included the fact that a randomized controlled trial wasn’t feasible, and that predisposing risk factors for seizure such as a history of seizure or of brain arteriovenous malformations were underrepresented, the researchers said.

“The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety,” they concluded.

This study was funded by Astellas Pharma and Medivation (acquired by Pfizer in September 2016), the co-developers of enzalutamide. Both sponsors participated in the design and conduct of the study as well as analysis and interpretation of the data, approval of the manuscript, and decision to submit for publication. Lead author Slovin reported a relationship with Bayer AG. A number of co-authors also reported relationships with industry, including Astellas Pharma, Medivation, and Pfizer.


Tagged with:

About author

Related Articles